Allena Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Allena Pharmaceuticals's earnings have been declining at an average annual rate of -12.9%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
-12.9%
Earnings growth rate
61.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -1,157.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Recent updates
First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment
Jul 19Allena Pharma reschedules special meeting to approve reverse stock split, shares fall
Jul 05Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days
Jan 08Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?
Dec 29
Allena Pharmaceuticals announces $10M bought deal
Dec 01Allena Pharma's ALLN-346 shows encouraging action in early-stage study
Nov 30Allena Pharmaceuticals (ALNA) Investor Presentation - Slideshow
Nov 11Allena Pharmaceuticals EPS misses by $0.01
Nov 09Revenue & Expenses Breakdown
How Allena Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -43 | 12 | 29 |
| 31 Mar 22 | 0 | -49 | 13 | 35 |
| 31 Dec 21 | 0 | -49 | 13 | 35 |
| 30 Sep 21 | 0 | -49 | 14 | 34 |
| 30 Jun 21 | 0 | -44 | 13 | 30 |
| 31 Mar 21 | 0 | -37 | 12 | 24 |
| 31 Dec 20 | 0 | -33 | 12 | 20 |
| 30 Sep 20 | 0 | -34 | 11 | 22 |
| 30 Jun 20 | 0 | -39 | 10 | 28 |
| 31 Mar 20 | 0 | -44 | 10 | 33 |
| 31 Dec 19 | 0 | -47 | 10 | 37 |
| 30 Sep 19 | 0 | -46 | 10 | 36 |
| 30 Jun 19 | 0 | -42 | 10 | 32 |
| 31 Mar 19 | 0 | -39 | 10 | 30 |
| 31 Dec 18 | 0 | -36 | 9 | 26 |
| 30 Sep 18 | 0 | -33 | 9 | 24 |
| 30 Jun 18 | 0 | -28 | 8 | 20 |
| 31 Mar 18 | 0 | -24 | 6 | 17 |
| 31 Dec 17 | 0 | -22 | 5 | 16 |
| 30 Sep 17 | 0 | -21 | 5 | 16 |
| 30 Jun 17 | 0 | -23 | 4 | 18 |
| 31 Mar 17 | 0 | -24 | 4 | 19 |
| 31 Dec 16 | 0 | -25 | 4 | 20 |
Quality Earnings: ALNA.Q is currently unprofitable.
Growing Profit Margin: ALNA.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALNA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 12.9% per year.
Accelerating Growth: Unable to compare ALNA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: ALNA.Q has a negative Return on Equity (-1157.52%), as it is currently unprofitable.